Eisai’s Lecanemab: US FDA Showed Flexibility On Clinical Endpoint Results, Safety Database Size

 
• By Sue Sutter
Slinky
FDA showed some flexibility on data requirements for lecanemab given the serious nature of Alzheimer's disease. • Source: Shutterstock

More from Approvals

More from Product Reviews